title: Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration.
abstract: The role of inflammation in the progression of neurodegenerative disease remains unclear. We have shown that systemic bacterial insults accelerate disease progression in animals and in patients with Alzheimer's disease. Disease exacerbation is associated with exaggerated CNS inflammatory responses to systemic inflammation mediated by microglia that become 'primed' by the underlying neurodegeneration. The impact of systemic viral insults on existing neurodegenerative disease has not been investigated. Polyinosinic:polycytidylic acid (poly I:C) is a toll-like receptor-3 (TLR3) agonist and induces type I interferons, thus mimicking inflammatory responses to systemic viral infection. In the current study we hypothesized that systemic challenge with poly I:C, during chronic neurodegenerative disease, would amplify CNS inflammation and exacerbate disease. Using the ME7 model of prion disease and systemic challenge with poly I:C (12 mg/kg i.p.) we have shown an amplified expression of IFN-alpha and beta and of the pro-inflammatory genes IL-1beta and IL-6. Similarly amplified expression of specific IFN-dependent genes confirmed that type I IFNs were secreted and active in the brain and this appeared to have anti-inflammatory consequences. However, prion-diseased animals were susceptible to heightened acute sickness behaviour and acute neurological impairments in response to poly I:C and this treatment also accelerated disease progression in diseased animals without effect in normal animals. Increased apoptosis coupled with double-stranded RNA-dependent protein kinase (PKR) and Fas transcription suggested activation of interferon-dependent, pro-apoptotic pathways in the brain of ME7+poly I:C animals. That systemic poly I:C accelerates neurodegeneration has implications for the control of systemic viral infection during chronic neurodegeneration and indicates that type I interferon responses in the brain merit further study.
authors.affiliation: School of Biochemistry and Immunology, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland.
authors.forename: Robert
authors.initials: R
authors.lastname: Field
authors.forename: Suzanne
authors.initials: S
authors.lastname: Campion
authors.forename: Colleen
authors.initials: C
authors.lastname: Warren
authors.forename: Carol
authors.initials: C
authors.lastname: Murray
authors.forename: Colm
authors.initials: C
authors.lastname: Cunningham
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001522:Behavior, Animal; D001831:Body Temperature / Q000502:physiology; D001923:Brain Chemistry / Q000187:drug effects*; D016207:Cytokines / Q000096:biosynthesis; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology / Q000523:psychology; D007369:Interferon Inducers / Q000494:pharmacology*; D016898:Interferon-alpha / Q000096:biosynthesis*; D016899:Interferon-beta / Q000096:biosynthesis*; D053583:Interleukin-1beta / Q000096:biosynthesis*; D051379:Mice; D008810:Mice, Inbred C57BL; D009410:Nerve Degeneration / Q000139:chemically induced* / Q000473:pathology / Q000523:psychology; D011070:Poly I-C / Q000494:pharmacology*; D017096:Prion Diseases / Q000473:pathology / Q000821:virology; D011597:Psychomotor Performance / Q000502:physiology; D012313:RNA / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013238:Stereotaxic Techniques; D051196:Toll-Like Receptor 3 / Q000819:agonists*
chemical_list: D000998:Antiviral Agents; D016207:Cytokines; D007369:Interferon Inducers; D016898:Interferon-alpha; D053583:Interleukin-1beta; C519703:TLR3 protein, mouse; D051196:Toll-Like Receptor 3; D012313:RNA; D016899:Interferon-beta; D011070:Poly I-C
references.citation: Nat Med. 2006 Sep;12(9):1005-15
references.pmid: 16960575
references.citation: Eur J Immunol. 2009 Sep;39(9):2525-36
references.pmid: 19670379
references.citation: Neurobiol Dis. 2008 Apr;30(1):19-29
references.pmid: 18255301
references.citation: J Gen Virol. 1983 Jun;64 (Pt 6):1387-9
references.pmid: 6189965
references.citation: J Virol. 2009 Oct;83(19):9709-19
references.pmid: 19587041
references.citation: J Gen Virol. 1968 Sep;3(2):295-7
references.pmid: 5748908
references.citation: J Neuropathol Exp Neurol. 1983 Nov;42(6):615-26
references.pmid: 6685171
references.citation: Curr Opin Infect Dis. 2006 Oct;19(5):467-74
references.pmid: 16940871
references.citation: J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):788-9
references.pmid: 12754353
references.citation: Biochem Genet. 1998 Oct;36(9-10):311-22
references.pmid: 9919357
references.citation: Neuroscience. 2003;120(3):837-45
references.pmid: 12895523
references.citation: Nat Rev Immunol. 2006 Sep;6(9):644-58
references.pmid: 16932750
references.citation: Intervirology. 1986;25(2):103-10
references.pmid: 3013796
references.citation: J Neurosci. 2009 Mar 25;29(12):3948-55
references.pmid: 19321791
references.citation: FASEB J. 2005 Aug;19(10):1329-31
references.pmid: 15919760
references.citation: Brain. 2008 Jul;131(Pt 7):1880-94
references.pmid: 18504291
references.citation: Brain Behav Immun. 2010 Feb;24(2):306-15
references.pmid: 19861156
references.citation: Nat Med. 2004 Dec;10(12):1366-73
references.pmid: 15558055
references.citation: Neurobiol Dis. 2005 Mar;18(2):258-69
references.pmid: 15686954
references.citation: Arch Int Pharmacodyn Ther. 1964 Dec 1;152:277-84
references.pmid: 14265648
references.citation: Virology. 1996 May 15;219(2):339-49
references.pmid: 8638399
references.citation: Biochem Biophys Res Commun. 2004 Oct 15;323(2):556-64
references.pmid: 15369787
references.citation: J Neurosci. 2005 Oct 5;25(40):9275-84
references.pmid: 16207887
references.citation: J Neurovirol. 2004 Feb;10(1):29-40
references.pmid: 14982726
references.citation: Mol Neurodegener. 2007 Mar 16;2:5
references.pmid: 17367538
references.citation: Infect Immun. 1972 Oct;6(4):643-5
references.pmid: 4628902
references.citation: J Neurosci. 2007 Apr 18;27(16):4403-12
references.pmid: 17442825
references.citation: J Virol. 2000 Feb;74(3):1513-23
references.pmid: 10627563
references.citation: Trends Neurosci. 2000 Dec;23(12):618-25
references.pmid: 11137152
references.citation: Nature. 2001 Oct 18;413(6857):732-8
references.pmid: 11607032
references.citation: J Neuroimmunol. 2008 May 30;196(1-2):67-81
references.pmid: 18471898
references.citation: Ann N Y Acad Sci. 1977 Mar 4;284:676-80
references.pmid: 280156
references.citation: Mol Psychiatry. 2008 Mar;13(3):293-301
references.pmid: 17486106
references.citation: EMBO J. 1998 Dec 1;17(23):6888-902
references.pmid: 9843495
references.citation: Glia. 2003 Oct;44(1):1-12
references.pmid: 12951652
references.citation: Neuroscience. 2002;112(1):7-11
references.pmid: 12044467
references.citation: J Neurosci. 2005 Sep 28;25(39):8843-53
references.pmid: 16192374
references.citation: Neurobiol Aging. 2006 May;27(5):723-32
references.pmid: 15893410
references.citation: Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12
references.pmid: 18262679
references.citation: J Immunol. 2004 Sep 15;173(6):3916-24
references.pmid: 15356140
references.citation: J Virol. 2004 Jun;78(12):6143-50
references.pmid: 15163707
references.citation: Brain Res. 1999 Jul 17;835(1):46-61
references.pmid: 10448195
references.citation: J Immunol. 2006 Mar 15;176(6):3804-12
references.pmid: 16517751
references.citation: Brain Behav Immun. 2006 May;20(3):290-9
references.pmid: 16243480
references.citation: J Immunol. 2003 Apr 1;170(7):3565-71
references.pmid: 12646618
references.citation: Stroke. 2003 Sep;34(9):2126-31
references.pmid: 12920256
references.citation: Neurology. 2009 May 5;72(18):1570-5
references.pmid: 19414723
references.citation: J Gen Virol. 1969 Jul;5(1):149-50
references.pmid: 5387845
references.citation: J Immunol. 1983 May;130(5):2011-3
references.pmid: 6403616
references.citation: J Immunol. 2009 Jun 15;182(12):7353-63
references.pmid: 19494257
references.citation: Immunity. 2008 May;28(5):675-86
references.pmid: 18424188
references.citation: Biol Psychiatry. 2009 Feb 15;65(4):304-12
references.pmid: 18801476
references.citation: Neurodegeneration. 1995 Jun;4(2):203-7
references.pmid: 7583685
references.citation: Brain Res Bull. 2001 Dec;56(6):581-8
references.pmid: 11786245
references.citation: Immunol Cell Biol. 2004 Aug;82(4):410-4
references.pmid: 15283851
references.citation: Brain Behav Immun. 2007 May;21(4):490-502
references.pmid: 17321719
references.citation: J Neuroimmunol. 2005 Feb;159(1-2):12-9
references.pmid: 15652398
references.citation: J Neurosci Res. 2009 May 1;87(6):1381-8
references.pmid: 19115408
references.citation: Neurology. 2009 Sep 8;73(10):768-74
references.pmid: 19738171
references.citation: J Immunol. 1983 Aug;131(2):1038-43
references.pmid: 6306103
references.citation: Mol Cell Biol. 1988 Oct;8(10):4524-8
references.pmid: 2460745
references.citation: J Neurosci. 2004 Feb 11;24(6):1340-9
references.pmid: 14960605
references.citation: J Immunol. 2003 May 1;170(9):4776-84
references.pmid: 12707359
references.citation: Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):238-43
references.pmid: 15618403
references.citation: Nature. 2006 May 4;441(7089):101-5
references.pmid: 16625202